JP2020520368A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520368A5
JP2020520368A5 JP2019563558A JP2019563558A JP2020520368A5 JP 2020520368 A5 JP2020520368 A5 JP 2020520368A5 JP 2019563558 A JP2019563558 A JP 2019563558A JP 2019563558 A JP2019563558 A JP 2019563558A JP 2020520368 A5 JP2020520368 A5 JP 2020520368A5
Authority
JP
Japan
Prior art keywords
composition
particles
cancer
poly
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019563558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/079688 external-priority patent/WO2018210439A1/en
Publication of JP2020520368A publication Critical patent/JP2020520368A/ja
Publication of JP2020520368A5 publication Critical patent/JP2020520368A5/ja
Priority to JP2022157413A priority Critical patent/JP2022188159A/ja
Priority to JP2024131720A priority patent/JP2024160312A/ja
Pending legal-status Critical Current

Links

JP2019563558A 2017-05-17 2017-11-17 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 Pending JP2020520368A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022157413A JP2022188159A (ja) 2017-05-17 2022-09-30 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
JP2024131720A JP2024160312A (ja) 2017-05-17 2024-08-08 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17171617 2017-05-17
EP17171617.8 2017-05-17
EP17382301 2017-05-26
EP17382301.4 2017-05-26
EP17200469 2017-11-07
EP17200469.9 2017-11-07
PCT/EP2017/079688 WO2018210439A1 (en) 2017-05-17 2017-11-17 Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022157413A Division JP2022188159A (ja) 2017-05-17 2022-09-30 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物

Publications (2)

Publication Number Publication Date
JP2020520368A JP2020520368A (ja) 2020-07-09
JP2020520368A5 true JP2020520368A5 (https=) 2021-01-07

Family

ID=64273459

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019563558A Pending JP2020520368A (ja) 2017-05-17 2017-11-17 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
JP2022157413A Pending JP2022188159A (ja) 2017-05-17 2022-09-30 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
JP2024131720A Pending JP2024160312A (ja) 2017-05-17 2024-08-08 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022157413A Pending JP2022188159A (ja) 2017-05-17 2022-09-30 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
JP2024131720A Pending JP2024160312A (ja) 2017-05-17 2024-08-08 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物

Country Status (10)

Country Link
US (6) US10849921B2 (https=)
EP (2) EP4122449A1 (https=)
JP (3) JP2020520368A (https=)
CN (2) CN110831581A (https=)
AU (2) AU2017414660A1 (https=)
CA (1) CA3063805C (https=)
DK (1) DK3448363T3 (https=)
ES (1) ES2924138T3 (https=)
PL (1) PL3448363T3 (https=)
WO (1) WO2018210439A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3319587B1 (en) * 2015-11-17 2019-08-21 Bioncotech Therapeutics, S.L Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
US10849921B2 (en) * 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
WO2020072366A1 (en) * 2018-10-01 2020-04-09 The Regents Of The University Of California Methods for treating cancer with double stranded rna sensor activators and adoptive cell therapy
WO2020077077A1 (en) * 2018-10-10 2020-04-16 The Regents Of The University Of California Combination immunotherapies
CN117338800A (zh) 2018-11-01 2024-01-05 阿尔法陶医疗有限公司 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活
WO2020104628A1 (en) * 2018-11-21 2020-05-28 Bioncotech Therapeutics S.L Nanoplexed poly(i:c) formulations and uses thereof
UY39877A (es) * 2021-07-30 2023-02-28 Esteban Celis Actividad biológica multidimensional optimizada de poli-iclc con tamaño y formulación de componentes
CN114525253B (zh) * 2022-03-09 2024-03-15 南开大学 一种脂多糖诱导的外泌体及其应用
US20240091348A1 (en) 2022-09-20 2024-03-21 Highlight Therapeutics, S.L. Novel compositions based on polyinosinic-polycytidylic acid

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60021354T2 (de) * 1999-02-15 2006-04-27 Nippon Shinyaku Co., Ltd. Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung
AU2003248791A1 (en) 2002-07-03 2005-11-09 Oncovir, Inc. Method for preparation of poly-iclc and uses thereof
US7927792B2 (en) 2002-11-18 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Targeted double stranded RNA mediated cell killing
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
JP4861036B2 (ja) 2006-03-31 2012-01-25 リンテック株式会社 剥離シートおよびその製造方法
WO2008057696A2 (en) 2006-10-10 2008-05-15 Juvaris Biotherapeutics, Inc. Compositions of pattern recognition receptor-ligand: lipid complexes and methods of use thereof
KR100958293B1 (ko) 2008-03-27 2010-05-19 단국대학교 산학협력단 테오필린에 의해 표적 특이적 ｒｎａ 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 ｉ 리보자임
WO2009130301A1 (en) * 2008-04-25 2009-10-29 Institut Gustave Roussy Improved treatment of cancer using tlr3 agonists in combination with another therapeutic agent
US9006406B2 (en) * 2008-12-22 2015-04-14 Alexander Levitzki EGFR-homing double-stranded RNA vector for systemic cancer treatment
ES2368963B1 (es) * 2009-07-04 2012-10-10 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado.
CN102988303A (zh) 2011-09-15 2013-03-27 天津泽世德生物医药有限公司 一种多聚肌苷酸多聚胞苷酸冻干粉针的制备方法
US20140234373A1 (en) 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance
US9226936B2 (en) 2011-10-28 2016-01-05 The Wistar of Anatomy and Biology Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
WO2013087083A1 (en) 2011-12-15 2013-06-20 Biontech Ag Particles comprising single stranded rna and double stranded rna for immunomodulation
KR102240042B1 (ko) 2012-05-03 2021-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
WO2014165296A1 (en) 2013-03-12 2014-10-09 Multicell Immunotherapeutics, Inc. Methods and formulations to achieve tumor targeted double stranded rna mediated cell death
JP6629216B2 (ja) * 2013-11-06 2020-01-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤
CN103599071B (zh) 2013-11-08 2016-01-27 杭州美亚药业股份有限公司 一种双链聚肌胞干粉的制备方法
KR102589295B1 (ko) 2014-05-14 2023-10-13 타르그이뮨 테라퓨틱스 아게 개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터
EP4353257A3 (en) 2015-04-13 2024-08-07 CureVac Manufacturing GmbH Method for producing rna compositions
SG11201708760PA (en) * 2015-05-05 2017-11-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
EP3319587B1 (en) * 2015-11-17 2019-08-21 Bioncotech Therapeutics, S.L Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
CN109715205A (zh) 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
US10849921B2 (en) * 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine

Similar Documents

Publication Publication Date Title
JP2020520368A5 (https=)
Liu et al. Tumor microenvironment‐responsive nanoparticles amplifying STING signaling pathway for cancer immunotherapy
Liu et al. Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice
Han et al. Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer
Feng et al. Enhancing triple negative breast cancer immunotherapy by ICG‐templated self‐assembly of paclitaxel nanoparticles
Li et al. Nanotechnology: breaking the current treatment limits of lung cancer
Shen et al. Alendronate triggered dual‐cascade targeting prodrug nanoparticles for enhanced tumor penetration and STING activation of osteosarcoma
Guorgui et al. Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin's lymphoma in mice
Norouzi et al. Injectable hydrogel-based drug delivery systems for local cancer therapy
Bauleth‐Ramos et al. Acetalated dextran nanoparticles loaded into an injectable alginate cryogel for combined chemotherapy and cancer vaccination
Zhang et al. Metal coordination‐driven assembly of stimulator of interferon genes‐activating nanoparticles for tumor chemo‐immunotherapy
Mu et al. Nanoparticles for imaging and treatment of metastatic breast cancer
Kang et al. Liver-targeted siRNA delivery by polyethylenimine (PEI)-pullulan carrier
Yu et al. Synergy of immunostimulatory genetherapy with immune checkpoint blockade motivates immune response to eliminate cancer
Chen et al. Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy
Chen et al. iRGD tumor-penetrating peptide-modified nano-delivery system based on a marine sulfated polysaccharide for enhanced anti-tumor efficiency against breast cancer
Liu et al. Nanoparticles for chemoimmunotherapy against triple-negative breast cancer
Wang et al. Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: a comparative study of molecular inhibitors and siRNA therapeutics
Wu et al. Promote intratumoral drug release and penetration to counteract docetaxel‐induced metastasis by photosensitizer‐modified red blood cell membrane‐coated nanoparticle
US10632081B2 (en) Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis
Mollica et al. Delivery methods of camptothecin and its hydrosoluble analogue irinotecan for treatment of colorectal cancer
Wang et al. Polysaccharide nanodonuts for photochemotherapy‐amplified immunogenic cell death to potentiate systemic antitumor immunity against hepatocellular carcinoma
Li et al. EGF‐functionalized lipid–polymer hybrid nanoparticles of 5‐fluorouracil and sulforaphane with enhanced bioavailability and anticancer activity against colon carcinoma
Jiang et al. Nanoscale coordination polymer synergizes photodynamic therapy and toll-like receptor activation for enhanced antigen presentation and antitumor immunity
Li et al. Co-delivery of Interleukin-12 and doxorubicin loaded Nano-delivery system for enhanced immunotherapy with polarization toward M1-type Macrophages